Yi‐Hsiang Huang - Concepedia

Author

Yi‐Hsiang Huang

Also Known As

Chien-Hung Chen, Chi‐Tan Hu, Chun‐Ting Chen, Edoardo Giannini, Huang Y.-H., Huang, Y.-H., Huang, YH, Huang, Yi, Huang, Yi-Hsiang, I Elovaara

817

Publications

22.6K

Citations

H-Index

221

Concepts

All Affiliations

Taipei Veterans General Hospital National Yang Ming Chiao Tung University National Yang Ming University Hospital National Taipei University

About

Yi‐Hsiang Huang is an author at Taipei Veterans General Hospital specializing in medicine, hepatology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	99	10K
2	Health Sciences	20	33	5.7K
3	Public Health	5	5	301
4	Engineering	3	3	48
5	Natural Sciences	1	1	55

Yi‐Hsiang Huang

359

Publications

20.5K

Citations

H-Index

Page 1

	Year	Citations
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Jordi Bruix, Shukui Qin, Philippe Merle, The Lancet HepatologyMedicineSorafenib TreatmentClinical TrialsPharmacotherapy	2016	3.6K
NASH limits anti-tumour surveillance in immunotherapy-treated HCC Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Nature	2021	1.2K
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma Jaw‐Ching Wu, Yi‐Hsiang Huang, Gar‐Yang Chau, Journal of Hepatology Hepatitis DHepatologyViral HepatitisMedicineHepatitis B	2009	430
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Shukui Qin, Minshan Chen, Ann‐Lii Cheng, The Lancet Surgical OncologyHepatologyMedicinePathologyHigh-risk Hepatocellular Carcinoma	2023	415
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Josep M. Llovet, Masatoshi Kudo, Philippe Merle, The Lancet Oncology OncologyHepatologyMedicineClinical TrialsPembrolizumab Versus Lenvatinib	2023	364
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial Richard S. Finn, Philippe Merle, Alessandro Granito, Journal of Hepatology Additional AnalysesOncologyMedicineClinical TrialsSequential Treatment	2018	350
Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B Yi‐Hsiang Huang, Liang-Tsai Hsiao, Ying-Chung Hong, Journal of Clinical Oncology	2013	323
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements Masatoshi Kudo, Kwang‐Hyub Han, Sheng-Long Ye, Liver Cancer Surgical OncologyIntermediate-stage HccPathologyLiver FunctionHepatic Disorders	2020	295
Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems Po‐Hong Liu, Chia‐Yang Hsu, Cheng‐Yuan Hsia, Journal of Hepatology HepatologyMedicineHistopathologyPathologyLiver Cancer	2015	266
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO L.-T. Chen, Erika Martinelli, Ann‐Lii Cheng, Annals of Oncology HepatologyMedicineCancer ManagementAdvanced/relapsed Hepatocellular CarcinomaPathology	2020	233

Page 1